Humasis Co. Ltd Cash Flow Conversion Efficiency
Humasis Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Humasis Co. Ltd (205470) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.98 Billion ≈ $6.08 Million USD) by net assets (₩248.94 Billion ≈ $168.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Humasis Co. Ltd (2016–2024)
Cash flow conversion efficiency of Humasis Co. Ltd from 2016 to 2024. This chart illustrates how Humasis Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Humasis Co. Ltd for real-time trading data and today's change.
Humasis Co. Ltd Cash Flow Conversion Ratio Explained
Humasis Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Humasis Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Humasis Co. Ltd ranked by their cash flow conversion efficiency. Also see market cap of Humasis Co. Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metro Mining Limited
F:6ME
|
-0.025x |
|
Iris Acquisition Corp II
NYSE:IRAB
|
0.000x |
|
KYE Systems Corp
TW:2365
|
0.002x |
|
Terra Santa Propriedades Agrícolas S.A.
SA:LAND3
|
0.116x |
|
Soechi Lines Tbk
JK:SOCI
|
0.011x |
|
Hong Leong Capital Bhd
KLSE:5274
|
-0.159x |
|
Frauenthal Holding AG
VI:FKA
|
-0.048x |
|
Ascom Holding AG
SW:ASCN
|
0.200x |
Annual Cash Flow Conversion Efficiency for Humasis Co. Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Humasis Co. Ltd from 2016 to 2024. Review 205470 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩229.26 Billion ≈ $155.37 Million |
₩30.37 Billion ≈ $20.58 Million |
0.132x | +168.60% |
| 2023-12-31 | ₩287.33 Billion ≈ $194.72 Million |
₩-55.48 Billion ≈ $-37.60 Million |
-0.193x | -133.05% |
| 2022-12-31 | ₩346.73 Billion ≈ $234.98 Million |
₩202.60 Billion ≈ $137.30 Million |
0.584x | -42.43% |
| 2021-12-31 | ₩202.01 Billion ≈ $136.90 Million |
₩205.02 Billion ≈ $138.94 Million |
1.015x | +246.69% |
| 2020-12-31 | ₩48.84 Billion ≈ $33.10 Million |
₩14.30 Billion ≈ $9.69 Million |
0.293x | +472.45% |
| 2019-12-31 | ₩15.24 Billion ≈ $10.33 Million |
₩779.58 Million ≈ $528.31K |
0.051x | +210.38% |
| 2018-12-31 | ₩16.13 Billion ≈ $10.93 Million |
₩-747.08 Million ≈ $-506.29K |
-0.046x | +75.66% |
| 2017-12-31 | ₩15.60 Billion ≈ $10.57 Million |
₩-2.97 Billion ≈ $-2.01 Million |
-0.190x | -1468.41% |
| 2016-12-31 | ₩10.86 Billion ≈ $7.36 Million |
₩151.11 Million ≈ $102.40K |
0.014x | -- |
About Humasis Co. Ltd
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more